{
    "abstract": "Background: We evaluated antibody persistence up to 68 months (M) post-vaccination with a quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine (MenACWY-TT) or a licensed monovalent MenC conjugate vaccine (MenC-CRM197) and subsequent booster responses to MenACWY-TT in healthy European children. Methods: In the initial study (NCT00674583), healthy children, 2\u201310 years of age, were randomized to receive a single dose of either MenACWY-TT or MenC-CRM197. In the follow-up study, we present the persistence at 32, 44, 56, and 68 M post-vaccination, overall and stratified by age (2\u20135 and 6\u201310 years), and the immunogenicity and safety of MenACWY-TT administered to all study participants at M68 post-primary vaccination. Results: At M68, 33.3% (age group 2\u20135 years) and 47.1% (age group 6\u201310 years) of the children vaccinated with MenACWY-TT, and 50.0% (age group 2\u20135 years) and 75.9% (age group 6\u201310 years) vaccinated with MenC-CRM197 retained titers \u22651:8 for MenC, as assessed by a serum bactericidal assay using rabbit complement (rSBA). In the MenACWY-TT recipients, the percentages of children retaining rSBA titers \u22651:8 for MenA, MenW, and MenY were 81.7%, 47.3% and 66.7% in age group 2\u20135 years and 91.8%, 58,8% and 76.5% in age group 6\u201310 years, respectively. The booster dose induced robust responses (100% for all serogroups) and was well-tolerated. Conclusions: Antibody persistence (rSBA titers \u2265 1:8) for serogroups A, W and Y was observed in more than 50.0% of the children 68 M after receiving one dose of MenACWY-TT; for MenC, antibody persistence was observed in more than one third of MenACWY-TT and more than half of MenC-CRM197 recipients. Vaccination with a booster dose of MenACWY-TT induced robust immune responses for all serogroups.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.04.063",
            "firstpage": "B51",
            "issn": "0264410X",
            "lastpage": "B63",
            "pmid": "19477562",
            "pub_year": 2009,
            "title": "Global epidemiology of meningococcal disease",
            "volume": "27"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Julie A.",
                    "initial": "J.A.",
                    "last": "Bettinger"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Jelfs"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "McIntyre"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Marco A.P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.032",
            "firstpage": "B26",
            "issn": "0264410X",
            "lastpage": "B36",
            "pmid": "22178525",
            "pub_year": 2012,
            "title": "The changing and dynamic epidemiology of meningococcal disease",
            "volume": "30"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0020": null,
        "b0025": null,
        "b0030": {
            "authors": [
                {
                    "first": "Wiebke",
                    "initial": "W.",
                    "last": "Hellenbrand"
                },
                {
                    "first": "Johannes",
                    "initial": "J.",
                    "last": "Elias"
                },
                {
                    "first": "Ole",
                    "initial": "O.",
                    "last": "Wichmann"
                },
                {
                    "first": "Manuel",
                    "initial": "M.",
                    "last": "Dehnert"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Frosch"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Vogel"
                }
            ],
            "doi": "10.1016/j.jinf.2012.09.008",
            "firstpage": "48",
            "issn": "01634453",
            "lastpage": "56",
            "pmid": "23043893",
            "pub_year": 2013,
            "title": "Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine",
            "volume": "66"
        },
        "b0035": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Parent du Ch\u00e2telet"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Barboza"
                },
                {
                    "first": "M. K.",
                    "initial": "M.K.",
                    "last": "Taha"
                }
            ],
            "issn": "1025496X",
            "pmid": "22687826",
            "pub_year": 2012,
            "title": "W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012",
            "volume": "17"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Jacobsson"
                },
                {
                    "first": "Markku",
                    "initial": "M.",
                    "last": "Kuusi"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Pace"
                },
                {
                    "first": "Maria J.",
                    "initial": "M.J.",
                    "last": "Sim\u00f5es"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Skoczynska"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Maija",
                    "initial": "M.",
                    "last": "Toropainen"
                },
                {
                    "first": "Georgina",
                    "initial": "G.",
                    "last": "Tzanakaki"
                }
            ],
            "doi": "10.4161/hv.21794",
            "firstpage": "1907",
            "issn": "21645515",
            "lastpage": "1911",
            "pmid": "23032167",
            "pub_year": 2012,
            "title": "Meningococcal serogroup Y emergence in Europe: Update 2011",
            "volume": "8"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Anna L.",
                    "initial": "A.L.",
                    "last": "Goodman"
                },
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Masuet-Aumatell"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Halbert"
                },
                {
                    "first": "Jane N.",
                    "initial": "J.N.",
                    "last": "Zuckerman"
                }
            ],
            "doi": "10.4269/ajtmh.13-0763",
            "firstpage": "281",
            "issn": "00029637",
            "lastpage": "286",
            "pmid": "24891461",
            "pub_year": 2014,
            "title": "Awareness of meningococcal disease among travelers from the United Kingdom to the meningitis belt in Africa",
            "volume": "91"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Gray"
                },
                {
                    "first": "Ed",
                    "initial": "E.",
                    "last": "Kaczmarski"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1093/cid/ciu881",
            "firstpage": "578",
            "issn": "10584838",
            "lastpage": "585",
            "pmid": "25389259",
            "pub_year": 2015,
            "title": "Increase in endemic neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in england and wales",
            "volume": "60"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Raquel",
                    "initial": "R.",
                    "last": "Abad"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "V\u00e1zquez"
                }
            ],
            "doi": "10.1016/j.jinf.2016.06.010",
            "firstpage": "296",
            "issn": "01634453",
            "lastpage": "297",
            "pmid": "27387450",
            "pub_year": 2016,
            "title": "Early evidence of expanding W ST-11 CC meningococcal incidence in Spain",
            "volume": "73"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Cl\u00e9ment",
                    "initial": "C.",
                    "last": "Bassi"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Taha"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Merle"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Hong"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "L\u00e9vy-Bruhl"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Barret"
                },
                {
                    "first": "I. Mounchetrou",
                    "initial": "I.M.",
                    "last": "Njoya"
                }
            ],
            "doi": "10.2807/1560-7917.ES.2017.22.28.30574",
            "issn": "1025496X",
            "pmid": "28749333",
            "pub_year": 2017,
            "title": "A cluster of invasive meningococcal disease (IMD) caused by neisseria meningitidis serogroup w among university students, france, february to may 2017",
            "volume": "22"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Russcher"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Fanoy"
                },
                {
                    "first": "G. D.J.",
                    "initial": "G.D.J.",
                    "last": "van Olden"
                },
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Graafland"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "van der Ende"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Knol"
                }
            ],
            "doi": "10.2807/1560-7917.ES.2017.22.23.30549",
            "issn": "1025496X",
            "pmid": "28661395",
            "pub_year": 2017,
            "title": "Necrotising fasciitis as atypical presentation of infection with emerging Neisseria meningitidis serogroup W (Menw) clonal complex 11, the Netherlands, March 2017",
            "volume": "22"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "K. J.",
                    "initial": "K.J.",
                    "last": "Scott"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Ure"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Smith"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Lindsay"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Stenmark"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Jacobsson"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Fredlund"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Cameron"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Smith-Palmer"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "McMenamin"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Gray"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ladhani"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Molling"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.2807/1560-7917.ES.2016.21.45.30395",
            "issn": "1025496X",
            "pmid": "27918265",
            "pub_year": 2016,
            "title": "An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup w strain, Scotland and Sweden, July to August 2015",
            "volume": "21"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Luis",
                    "initial": "L.",
                    "last": "J\u00f3dar"
                },
                {
                    "first": "Ian M.",
                    "initial": "I.M.",
                    "last": "Feavers"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Salisbury"
                },
                {
                    "first": "Dan M.",
                    "initial": "D.M.",
                    "last": "Granoff"
                }
            ],
            "doi": "10.1016/S0140-6736(02)08416-7",
            "firstpage": "1499",
            "issn": "01406736",
            "lastpage": "1508",
            "pmid": "11988262",
            "pub_year": 2002,
            "title": "Development of vaccines against meningococcal disease",
            "volume": "359"
        },
        "b0080": null,
        "b0085": {
            "authors": [
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Rabab Zehra",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar",
                    "initial": "Z.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1179/2047773214Y.0000000126",
            "firstpage": "11",
            "issn": "20477724",
            "lastpage": "20",
            "pmid": "24548156",
            "pub_year": 2014,
            "title": "Global practices of meningococcal vaccine use and impact on invasive disease",
            "volume": "108"
        },
        "b0090": null,
        "b0095": null,
        "b0100": {
            "authors": [
                {
                    "first": "Ziad A.",
                    "initial": "Z.A.",
                    "last": "Memish"
                },
                {
                    "first": "Ghassan",
                    "initial": "G.",
                    "last": "Dbaibo"
                },
                {
                    "first": "May",
                    "initial": "M.",
                    "last": "Montellano"
                },
                {
                    "first": "Valsan P.",
                    "initial": "V.P.",
                    "last": "Verghese"
                },
                {
                    "first": "Hemant",
                    "initial": "H.",
                    "last": "Jain"
                },
                {
                    "first": "A. P.",
                    "initial": "A.P.",
                    "last": "Dubey"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Salvacion",
                    "initial": "S.",
                    "last": "Gatchalian"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0b013e31820e6e02",
            "firstpage": "e56",
            "issn": "08913668",
            "lastpage": "e62",
            "pmid": "21278617",
            "pub_year": 2011,
            "title": "Immunogenicity of a single dose of tetravalent meningococcal serogroups a, c, w-135, and y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-acwy polysaccharide vaccine with an acceptable safety profile",
            "volume": "30"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forst\u00e9n"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.22165",
            "firstpage": "1882",
            "issn": "21645515",
            "lastpage": "1891",
            "pmid": "23032168",
            "pub_year": 2012,
            "title": "A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine in children aged 2-10 y",
            "volume": "8"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Devayani",
                    "initial": "D.",
                    "last": "Kolhe"
                },
                {
                    "first": "Carmen I.",
                    "initial": "C.I.",
                    "last": "Baccarini"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                }
            ],
            "doi": "10.1097/INF.0000000000000866",
            "firstpage": "1236",
            "issn": "08913668",
            "lastpage": "1243",
            "pmid": "26237742",
            "pub_year": 2015,
            "title": "Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults : An open, randomized trial",
            "volume": "34"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Devayani",
                    "initial": "D.",
                    "last": "Kolhe"
                },
                {
                    "first": "Carmen I.",
                    "initial": "C.I.",
                    "last": "Baccarini"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                }
            ],
            "doi": "10.1097/INF.0000000000001123",
            "firstpage": "662",
            "issn": "08913668",
            "lastpage": "672",
            "pmid": "26928521",
            "pub_year": 2016,
            "title": "Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and y tetanus toxoid conjugate vaccine in healthy children",
            "volume": "35"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forsten"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1080/21645515.2015.1058457",
            "firstpage": "132",
            "issn": "21645515",
            "lastpage": "139",
            "pmid": "26575983",
            "pub_year": 2016,
            "title": "Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine",
            "volume": "12"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Cressida",
                    "initial": "C.",
                    "last": "Auckland"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Gray"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1086/509619",
            "firstpage": "1745",
            "issn": "00221899",
            "lastpage": "1752",
            "pmid": "17109348",
            "pub_year": 2006,
            "title": "Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom",
            "volume": "194"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Shane",
                    "initial": "S.",
                    "last": "Christensen"
                },
                {
                    "first": "Bikash",
                    "initial": "B.",
                    "last": "Verma"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.02.049",
            "firstpage": "2175",
            "issn": "0264410X",
            "lastpage": "2182",
            "pmid": "25744224",
            "pub_year": 2015,
            "title": "Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination",
            "volume": "33"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Ameneh",
                    "initial": "A.",
                    "last": "Khatami"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Davis"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Layton"
                },
                {
                    "first": "Tessa",
                    "initial": "T.",
                    "last": "John"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrjlin"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Dobson"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.02.046",
            "firstpage": "2831",
            "issn": "0264410X",
            "lastpage": "2838",
            "pmid": "22394992",
            "pub_year": 2012,
            "title": "Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations",
            "volume": "30"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "Giuseppe L.",
                    "initial": "G.L.",
                    "last": "Ciavarro"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.4161/hv.6.11.12849",
            "firstpage": "881",
            "issn": "15548600",
            "lastpage": "887",
            "pmid": "21339701",
            "pub_year": 2010,
            "title": "Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents",
            "volume": "6"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Jacobson"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Allen",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1097/INF.0b013e318279ac38",
            "firstpage": "e170",
            "issn": "08913668",
            "lastpage": "e177",
            "pmid": "23114372",
            "pub_year": 2013,
            "title": "Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents",
            "volume": "32"
        },
        "b0150": {
            "authors": [
                {
                    "first": "David M.",
                    "initial": "D.M.",
                    "last": "Vu"
                },
                {
                    "first": "Jo Anne",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Zuno-Mitchell"
                },
                {
                    "first": "Josefa V.",
                    "initial": "J.V.",
                    "last": "Dela Cruz"
                },
                {
                    "first": "Dan M.",
                    "initial": "D.M.",
                    "last": "Granoff"
                }
            ],
            "doi": "10.1086/500512",
            "firstpage": "821",
            "issn": "00221899",
            "lastpage": "828",
            "pmid": "16479517",
            "pub_year": 2006,
            "title": "Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine",
            "volume": "193"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Edward B.",
                    "initial": "E.B.",
                    "last": "Kaczmarski"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/S0140-6736(04)16725-1",
            "firstpage": "365",
            "issn": "01406736",
            "lastpage": "367",
            "pmid": "15276396",
            "pub_year": 2004,
            "title": "Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction",
            "volume": "364"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Trotter"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/CVI.00529-09",
            "firstpage": "840",
            "issn": "15566811",
            "lastpage": "847",
            "pmid": "20219881",
            "pub_year": 2010,
            "title": "Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity",
            "volume": "17"
        },
        "b0165": null,
        "b0170": null,
        "b0175": {
            "authors": [
                {
                    "first": "Michael T.",
                    "initial": "M.T.",
                    "last": "Brady"
                },
                {
                    "first": "Henry H.",
                    "initial": "H.H.",
                    "last": "Bernstein"
                },
                {
                    "first": "Carrie L.",
                    "initial": "C.L.",
                    "last": "Byington"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Margaret C.",
                    "initial": "M.C.",
                    "last": "Fisher"
                },
                {
                    "first": "Mary P.",
                    "initial": "M.P.",
                    "last": "Glode"
                },
                {
                    "first": "Mary Anne",
                    "initial": "M.A.",
                    "last": "Jackson"
                },
                {
                    "first": "Harry L.",
                    "initial": "H.L.",
                    "last": "Keyserling"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Kimberlin"
                },
                {
                    "first": "Yvonne A.",
                    "initial": "Y.A.",
                    "last": "Maldonado"
                },
                {
                    "first": "Walter A.",
                    "initial": "W.A.",
                    "last": "Orenstein"
                },
                {
                    "first": "Gordon E.",
                    "initial": "G.E.",
                    "last": "Schutze"
                },
                {
                    "first": "Rodney E.",
                    "initial": "R.E.",
                    "last": "Willoughby"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Bortolussi"
                },
                {
                    "first": "Marc A.",
                    "initial": "M.A.",
                    "last": "Fischer"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Gellin"
                },
                {
                    "first": "Richard L.",
                    "initial": "R.L.",
                    "last": "Gorman"
                },
                {
                    "first": "Lucia",
                    "initial": "L.",
                    "last": "Lee"
                },
                {
                    "first": "R. Douglas",
                    "initial": "R.D.",
                    "last": "Pratt"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Seward"
                },
                {
                    "first": "Jeffrey R.",
                    "initial": "J.R.",
                    "last": "Starke"
                },
                {
                    "first": "Jack",
                    "initial": "J.",
                    "last": "Swanson"
                },
                {
                    "first": "Tina Q.",
                    "initial": "T.Q.",
                    "last": "Tan"
                }
            ],
            "doi": "10.1542/peds.2011-2380",
            "firstpage": "1213",
            "issn": "00314005",
            "lastpage": "1218",
            "pmid": "22123893",
            "pub_year": 2011,
            "title": "Meningococcal conjugate vaccines policy update: Booster dose recommendations",
            "volume": "128"
        },
        "b0180": {
            "authors": [
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ram"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "De Tora"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Anemona"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.10.068",
            "firstpage": "29",
            "issn": "0264410X",
            "lastpage": "34",
            "pmid": "22075087",
            "pub_year": 2011,
            "title": "Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source",
            "volume": "30"
        },
        "b0185": {
            "authors": [
                {
                    "first": "E. D.G.",
                    "initial": "E.D.G.",
                    "last": "McIntosh"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.019",
            "firstpage": "4414",
            "issn": "0264410X",
            "lastpage": "4421",
            "pmid": "26187262",
            "pub_year": 2015,
            "title": "Serum bactericidal antibody assays - The role of complement in infection and immunity",
            "volume": "33"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Castiglia"
                },
                {
                    "first": "Giorgio",
                    "initial": "G.",
                    "last": "Zoppi"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "de Martino"
                },
                {
                    "first": "Annaelisa",
                    "initial": "A.",
                    "last": "Tasciotti"
                },
                {
                    "first": "Diego",
                    "initial": "D.",
                    "last": "D'Agostino"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.05.009",
            "firstpage": "3363",
            "issn": "0264410X",
            "lastpage": "3370",
            "pmid": "27181507",
            "pub_year": 2016,
            "title": "Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers",
            "volume": "34"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Romain"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Kindler"
                },
                {
                    "first": "Uta",
                    "initial": "U.",
                    "last": "Walther"
                },
                {
                    "first": "Phu My",
                    "initial": "P.M.",
                    "last": "Tran"
                },
                {
                    "first": "Heidemarie",
                    "initial": "H.",
                    "last": "Pankow-Culot"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fischbach"
                },
                {
                    "first": "Dorothee",
                    "initial": "D.",
                    "last": "Kieninger-Baum"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Yaela",
                    "initial": "Y.",
                    "last": "Baine"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1007/s00431-012-1924-0",
            "firstpage": "601",
            "issn": "03406199",
            "lastpage": "612",
            "pmid": "23307281",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: Results of an open, randomised, controlled study",
            "volume": "172"
        },
        "b0200": {
            "authors": [
                {
                    "first": "Susan E.",
                    "initial": "S.E.",
                    "last": "Maslanka"
                },
                {
                    "first": "Linda L.",
                    "initial": "L.L.",
                    "last": "Gheesling"
                },
                {
                    "first": "Daniel E.",
                    "initial": "D.E.",
                    "last": "Libutti"
                },
                {
                    "first": "Kimberley B.J.",
                    "initial": "K.B.J.",
                    "last": "Donaldson"
                },
                {
                    "first": "Hani S.",
                    "initial": "H.S.",
                    "last": "Harakeh"
                },
                {
                    "first": "Janet K.",
                    "initial": "J.K.",
                    "last": "Dykes"
                },
                {
                    "first": "Francis F.",
                    "initial": "F.F.",
                    "last": "Arhin"
                },
                {
                    "first": "Sarvamangala J.N.",
                    "initial": "S.J.N.",
                    "last": "Devi"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Jay C.",
                    "initial": "J.C.",
                    "last": "Huang"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Kriz-Kuzemenska"
                },
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Lemmon"
                },
                {
                    "first": "Manon",
                    "initial": "M.",
                    "last": "Lorange"
                },
                {
                    "first": "Carla C.A.M.",
                    "initial": "C.C.A.M.",
                    "last": "Peeters"
                },
                {
                    "first": "Sally",
                    "initial": "S.",
                    "last": "Quataert"
                },
                {
                    "first": "Joseph Y.",
                    "initial": "J.Y.",
                    "last": "Tai"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                },
                {
                    "first": "Elaine L.",
                    "initial": "E.L.",
                    "last": "Mills"
                },
                {
                    "first": "Fraser E.",
                    "initial": "F.E.",
                    "last": "Ashton"
                },
                {
                    "first": "Jacob",
                    "initial": "J.",
                    "last": "Diepevaen"
                },
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Bielecki"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Bybel"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Cloutier"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "firstpage": "156",
            "issn": "1071412X",
            "lastpage": "167",
            "pmid": "9067649",
            "pub_year": 1997,
            "title": "Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays",
            "volume": "4"
        },
        "b0205": null,
        "b0210": {
            "authors": [
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Newcombe"
                }
            ],
            "doi": "10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E",
            "firstpage": "857",
            "issn": "02776715",
            "lastpage": "872",
            "pmid": "9595616",
            "pub_year": 1998,
            "title": "Two-sided confidence intervals for the single proportion: Comparison of seven methods",
            "volume": "17"
        },
        "b0215": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forsten"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1097/INF.0000000000000897",
            "firstpage": "e298",
            "issn": "08913668",
            "lastpage": "e307",
            "pmid": "26780033",
            "pub_year": 2015,
            "title": "Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal Serogroup C vaccine administered four years after primary vaccination using the same vaccines",
            "volume": "34"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forst\u00e9n"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.22166",
            "firstpage": "1892",
            "issn": "21645515",
            "lastpage": "1903",
            "pmid": "23032159",
            "pub_year": 2012,
            "title": "Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers",
            "volume": "8"
        },
        "b0225": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Raquel",
                    "initial": "R.",
                    "last": "Abad"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Trotter"
                },
                {
                    "first": "Fiona R.M.",
                    "initial": "F.R.M.",
                    "last": "van der Klis"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "Vazquez"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.07.083",
            "firstpage": "4477",
            "issn": "0264410X",
            "lastpage": "4486",
            "pmid": "23933336",
            "pub_year": 2013,
            "title": "Effectiveness of meningococcal serogroup C vaccine programmes",
            "volume": "31"
        },
        "b0230": {
            "authors": [
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Kaaijk"
                },
                {
                    "first": "Arie",
                    "initial": "A.",
                    "last": "van der Ende"
                },
                {
                    "first": "Guy",
                    "initial": "G.",
                    "last": "Berbers"
                },
                {
                    "first": "Germie P.J.M.",
                    "initial": "G.P.J.M.",
                    "last": "van den Dobbelsteen"
                },
                {
                    "first": "Nynke Y.",
                    "initial": "N.Y.",
                    "last": "Rots"
                }
            ],
            "doi": "10.1186/1471-2334-12-35",
            "issn": "14712334",
            "pmid": "22316426",
            "pub_year": 2012,
            "title": "Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands",
            "volume": "12"
        },
        "b0235": {
            "authors": [
                {
                    "first": "Richarda M.",
                    "initial": "R.M.",
                    "last": "de Voer"
                },
                {
                    "first": "Liesbeth",
                    "initial": "L.",
                    "last": "Mollema"
                },
                {
                    "first": "Rutger M.",
                    "initial": "R.M.",
                    "last": "Schepp"
                },
                {
                    "first": "Sabine C.",
                    "initial": "S.C.",
                    "last": "de Greeff"
                },
                {
                    "first": "Pieter G.M.",
                    "initial": "P.G.M.",
                    "last": "van Gageldonk"
                },
                {
                    "first": "Hester E.",
                    "initial": "H.E.",
                    "last": "de Melker"
                },
                {
                    "first": "Elisabeth A.M.",
                    "initial": "E.A.M.",
                    "last": "Sanders"
                },
                {
                    "first": "Guy A.M.",
                    "initial": "G.A.M.",
                    "last": "Berbers"
                },
                {
                    "first": "Fiona R.M.",
                    "initial": "F.R.M.",
                    "last": "van der Klis"
                }
            ],
            "doi": "10.1371/journal.pone.0012144",
            "issn": "19326203",
            "pmid": "20730091",
            "pub_year": 2010,
            "title": "Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine",
            "volume": "5"
        },
        "b0240": {
            "authors": [
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.04.012",
            "firstpage": "S3",
            "issn": "1054139X",
            "lastpage": "S11",
            "pmid": "27449148",
            "pub_year": 2016,
            "title": "The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines",
            "volume": "59"
        }
    },
    "body_text": [
        {
            "endOffset": 25039,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 25038,
                    "startOffset": 25033
                },
                "b0040": {
                    "endOffset": 25038,
                    "startOffset": 25033
                }
            },
            "secId": "s0005",
            "sentence": "However, epidemiological data from 2010 onwards demonstrate an increased total number and proportion of serogroup Y IMD cases (up to 50.0%) in various European regions such as the Scandinavian countries and Switzerland [2,8].",
            "startOffset": 24814,
            "title": "Introduction"
        },
        {
            "endOffset": 25342,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 25200,
                    "startOffset": 25195
                },
                "b0045": {
                    "endOffset": 25200,
                    "startOffset": 25195
                },
                "b0050": {
                    "endOffset": 25341,
                    "startOffset": 25334
                },
                "b0055": {
                    "endOffset": 25341,
                    "startOffset": 25334
                },
                "b0060": {
                    "endOffset": 25341,
                    "startOffset": 25334
                },
                "b0065": {
                    "endOffset": 25341,
                    "startOffset": 25334
                },
                "b0070": {
                    "endOffset": 25341,
                    "startOffset": 25334
                }
            },
            "secId": "s0005",
            "sentence": "Until recently, serogroups A and W were not frequently detected in Europe, but remained important causes of epidemic IMD in Africa, Asia and Latin America [7,9] However, the incidence of serogroup W disease has been rising in several European countries, underscoring a potential risk in Europe [10\u201314].",
            "startOffset": 25040,
            "title": "Introduction"
        },
        {
            "endOffset": 33969,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The MenA rSBA assay was performed at PHE with a specific MenA strain selected by GSK; the PHE\u2019s IQA process could not be implemented to monitor the stability of this MenA rSBA assay.",
            "startOffset": 33787,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 29418,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0195": {
                    "endOffset": 29417,
                    "startOffset": 29413
                }
            },
            "secId": "s0015",
            "sentence": "Immunogenicity data at M1 post-vaccination have been already published [39].",
            "startOffset": 29342,
            "title": "Study design and children"
        },
        {
            "endOffset": 45810,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although our hSBA results suggest comparable persistence of MenC antibody levels in the MenCCRM and ACWY-TT groups, due to the lack of correlation between rSBA and hSBA assays, a conclusion cannot be made about the long-term protection rendered by the two vaccines.",
            "startOffset": 45545,
            "title": "Discussion"
        },
        {
            "endOffset": 48238,
            "parents": [],
            "secId": "s0065",
            "sentence": "A booster dose of MenACWY-TT administered 68 M post-primary vaccination of 2\u201310 year old children induced a robust response for all serogroups.",
            "startOffset": 48095,
            "title": "Discussion"
        },
        {
            "endOffset": 33251,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The test was repeated if the titer for one control was invalid (outside of the acceptable range).",
            "startOffset": 33154,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 45442,
            "parents": [],
            "refoffsets": {
                "b0235": {
                    "endOffset": 45441,
                    "startOffset": 45437
                }
            },
            "secId": "s0065",
            "sentence": "Additionally, data from a large vaccination campaign in the Netherlands indicated that a single MenC conjugate vaccine, administered from 5 years of age on, resulted in a robust and persistent antibody response, while immunization at the age of 14 M was followed by a rapid decrease in antibody levels [47].",
            "startOffset": 45135,
            "title": "Discussion"
        },
        {
            "endOffset": 32556,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A randomized half of the participants had sera tested for hSBA-MenA and hSBA-MenC, and the other half for hSBA-MenW and hSBA-MenY at M32, M44, and M56.",
            "startOffset": 32405,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 28165,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 28164,
                    "startOffset": 28157
                },
                "b0185": {
                    "endOffset": 28164,
                    "startOffset": 28157
                },
                "b0190": {
                    "endOffset": 28164,
                    "startOffset": 28157
                }
            },
            "secId": "s0005",
            "sentence": "A correlation between the two assays, in particular for serogroups A, W and Y is a matter of debate [36\u201338].",
            "startOffset": 28057,
            "title": "Introduction"
        },
        {
            "endOffset": 33069,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Stability monitoring of the assays was performed over time.",
            "startOffset": 33010,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 39267,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At M68 after primary vaccination the percentages of children in the ACWY-TT group with hSBA titers \u22651:8 was 40.6% for MenA, 75.6% for MenC, 78.6% for MenW and 73.0% for MenY.",
            "startOffset": 39093,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 44809,
            "parents": [],
            "secId": "s0065",
            "sentence": "In line with this notion, although a similar trend could be observed in the two age groups, both seropositivity rate and GMTs tended to be consistently higher for each serogroup in the 6\u201310 years age group.",
            "startOffset": 44603,
            "title": "Discussion"
        },
        {
            "endOffset": 42783,
            "parents": [],
            "secId": "s0065",
            "sentence": "Accordingly, the drop in GMTs from M32 to M68 was higher for MenC and MenW (at least 2.5-fold) than for MenA and MenY (around 1.5-fold).",
            "startOffset": 42647,
            "title": "Discussion"
        },
        {
            "endOffset": 43660,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 43629,
                    "startOffset": 43619
                },
                "b0135": {
                    "endOffset": 43659,
                    "startOffset": 43655
                },
                "b0150": {
                    "endOffset": 43629,
                    "startOffset": 43619
                }
            },
            "secId": "s0065",
            "sentence": "Several studies have reported waning of functional antibody levels over the first 5 years after vaccination [24,27,30] especially for hSBA MenA [27].",
            "startOffset": 43511,
            "title": "Discussion"
        },
        {
            "endOffset": 41745,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Fatigue and headache were the most frequently reported solicited general symptoms in both groups (Fig. 3B).",
            "startOffset": 41638,
            "title": "Safety"
        },
        {
            "endOffset": 43303,
            "parents": [],
            "secId": "s0065",
            "sentence": "In Finland, percentages of MenACWY-TT vaccinees who retained rSBA titers \u22651:8, 4 years after MenACWY-TT vaccination (at 12\u201313 M of age), were between 40.4% (MenC) and 74.1% (MenA).",
            "startOffset": 43123,
            "title": "Discussion"
        },
        {
            "endOffset": 25691,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 25690,
                    "startOffset": 25686
                }
            },
            "secId": "s0005",
            "sentence": "MenC conjugate vaccines are effective in preventing IMD in infants and young children, and were associated with a reduction of MenC nasopharyngeal carriage [15].",
            "startOffset": 25530,
            "title": "Introduction"
        },
        {
            "endOffset": 24517,
            "parents": [],
            "secId": "s0005",
            "sentence": "Infants and children younger than 5 years of age have the highest incidence of IMD.",
            "startOffset": 24434,
            "title": "Introduction"
        },
        {
            "endOffset": 34148,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the persistence phase, only serious adverse events (SAEs) considered related to vaccination, study procedures or GSK concomitant medication were collected.",
            "startOffset": 33990,
            "title": "Safety assessments"
        },
        {
            "endOffset": 37032,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Main reasons for not participating can be found in Fig. 1.",
            "startOffset": 36974,
            "title": "Study participants"
        },
        {
            "endOffset": 39093,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "GMTs for all serogroups in the ACWY-TT 6\u201310 years age group and for serogroup C in the MenC-CRM 6\u201310 years group appeared slightly higher compared to the respective 2\u20135 years age group (Fig. 2 and Supplementary Digital Content 2).",
            "startOffset": 38863,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 27856,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 27855,
                    "startOffset": 27851
                }
            },
            "secId": "s0005",
            "sentence": "In the United States, one dose of MenACWY conjugate vaccine is recommended for 11\u201312 year olds followed by a booster dose at 16 years of age [35].",
            "startOffset": 27710,
            "title": "Introduction"
        },
        {
            "endOffset": 37565,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "In the booster phase of the study, one dose of MenACWY-TT was administered to all children (N = 241) from the total cohort for persistence M68 (179 in the ACWY-TT group, 62 in the MenC-CRM group).",
            "startOffset": 37369,
            "title": "Study participants"
        },
        {
            "endOffset": 45545,
            "parents": [],
            "secId": "s0065",
            "sentence": "Nevertheless, vaccination of infants remains crucial considering the disease burden in this age group.",
            "startOffset": 45443,
            "title": "Discussion"
        },
        {
            "endOffset": 36557,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The different time points were considered as categorical variables.",
            "startOffset": 36490,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28264,
            "parents": [],
            "secId": "s0005",
            "sentence": "To assess the value of each assay in our settings, we have decided to use both complement sources.",
            "startOffset": 28166,
            "title": "Introduction"
        },
        {
            "endOffset": 37369,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The ATP cohort for persistence M68 included 239 children (178 in the ACWY-TT group and 61 in the MenC-CRM group); the gender and racial distribution characteristics of the two groups were consistent with the primary study, except for a slight decrease in the percentage of females in the MenC-CRM group, in the extension study (Table 1).",
            "startOffset": 37032,
            "title": "Study participants"
        },
        {
            "endOffset": 35552,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "ATP was defined in both persistence and booster phases as vaccinated (with primary or booster vaccine, respectively) children who complied with all protocol-defined procedures and for whom results for at least one antigen were available at the respective time point.",
            "startOffset": 35286,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 43936,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 43935,
                    "startOffset": 43931
                },
                "b0220": {
                    "endOffset": 43795,
                    "startOffset": 43791
                }
            },
            "secId": "s0065",
            "sentence": "The seroprotective rates dropped to approximately 22% following one to three years post MenACWY-TT vaccination (12\u201323 month olds) [44] and down to 7% 5 years after 2 doses of MenACWY-CRM (2\u20135 year olds) and not more than 22% after 1 dose of MenACWY-CRM (6\u201310 year olds) [26].",
            "startOffset": 43661,
            "title": "Discussion"
        },
        {
            "endOffset": 47054,
            "parents": [],
            "secId": "s0065",
            "sentence": "Despite the long study duration leading to drops outs, our modelling analysis suggested no bias in the decrease in antibody titers.",
            "startOffset": 46923,
            "title": "Discussion"
        },
        {
            "endOffset": 27982,
            "parents": [],
            "secId": "s0005",
            "sentence": "Serum bactericidal activity against the four Neisseria meningitidis serogroups is determined using human or rabbit complement.",
            "startOffset": 27856,
            "title": "Introduction"
        },
        {
            "endOffset": 34741,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All other solicited symptoms were considered of grade 3 intensity if they prevented normal activity.",
            "startOffset": 34641,
            "title": "Safety assessments"
        },
        {
            "endOffset": 42929,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 42928,
                    "startOffset": 42918
                },
                "b0120": {
                    "endOffset": 42928,
                    "startOffset": 42918
                },
                "b0215": {
                    "endOffset": 42928,
                    "startOffset": 42918
                }
            },
            "secId": "s0065",
            "sentence": "Long-term antibody persistence has been assessed in recent studies and results are consistent with our data from the persistence phase [23,24,43].",
            "startOffset": 42783,
            "title": "Discussion"
        },
        {
            "endOffset": 36805,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The statistical analyses were performed using the SAS software (SAS Institute Inc., Cary, NC, United States).",
            "startOffset": 36696,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28595,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 28594,
                    "startOffset": 28590
                }
            },
            "secId": "s0005",
            "sentence": "The primary phase of this study (NCT00674583) conducted in children 2\u201310 years of age demonstrated non-inferiority of MenACWY-TT versus a commonly used monovalent MenC conjugate vaccine (MenC-CRM; Menjugate, GSK) in terms of vaccine response to MenC, assessed by a serum bactericidal assay using rabbit complement (rSBA-MenC) [39].",
            "startOffset": 28264,
            "title": "Introduction"
        },
        {
            "endOffset": 36373,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "To evaluate the bias that may have occurred due to the participants lost to follow-up and differences in relative retention of participants between groups after the vaccination, a longitudinal analysis was performed at the last persistence time point (M68) for each serogroup in the ACWY-TT group and for rSBA-MenC in the MenC-CRM group.",
            "startOffset": 36036,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 28056,
            "parents": [],
            "secId": "s0005",
            "sentence": "As the human source is scarce, rabbit complement is more frequently used.",
            "startOffset": 27983,
            "title": "Introduction"
        },
        {
            "endOffset": 28958,
            "parents": [],
            "secId": "s0005",
            "sentence": "The aim of this follow-up study was to evaluate for the first time (1) persistence to MenACWY-TT and Menjugate and (2) persistence in this age group of functional antibodies up to 68 M after primary vaccination and immunogenicity and safety of a MenACWY-TT booster dose administered at 68 M, in order to facilitate vaccination recommendations for a booster dose.",
            "startOffset": 28596,
            "title": "Introduction"
        },
        {
            "endOffset": 48453,
            "parents": [],
            "refoffsets": {
                "b0230": {
                    "endOffset": 48328,
                    "startOffset": 48324
                }
            },
            "secId": "s0065",
            "sentence": "It is thus key to establish a good surveillance system as indicated by Kaajik et al. [46], to estimate the decline in antibody titers and to facilitate decision making about the time point of a booster vaccination.",
            "startOffset": 48239,
            "title": "Discussion"
        },
        {
            "endOffset": 32674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Serum samples using rSBA and hSBA assays were tested at the Public Health England and GSK laboratories, respectively.",
            "startOffset": 32557,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 27478,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 27420,
                    "startOffset": 27416
                },
                "b0165": {
                    "endOffset": 27476,
                    "startOffset": 27472
                }
            },
            "secId": "s0005",
            "sentence": "Given the inverse relationship between waning antibodies and long-term protection, a booster dose of MenC conjugate vaccine during the second year of life was introduced in the United Kingdom in 2006 following infant vaccination [25] (replaced by the MenACWY conjugate vaccine in 2015 [33]).",
            "startOffset": 27187,
            "title": "Introduction"
        },
        {
            "endOffset": 29157,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase III, open, controlled study (NCT01266993) was conducted in 16 centers in Germany and 8 centers in France between January 2011 and May 2014.",
            "startOffset": 29007,
            "title": "Study design and children"
        },
        {
            "endOffset": 30586,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This study is registered at http://www.clinicaltrials.gov NCT01266993.",
            "startOffset": 30516,
            "title": "Study design and children"
        },
        {
            "endOffset": 34484,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The intensity of each symptom was graded on a three-level scale.",
            "startOffset": 34420,
            "title": "Safety assessments"
        },
        {
            "endOffset": 36973,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of the 414 children vaccinated in the primary study, 58.2\u201365.5% were included in the total cohort for persistence from M32 to M68 (Fig. 1).",
            "startOffset": 36834,
            "title": "Study participants"
        },
        {
            "endOffset": 33786,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Approximately four times a year, IQA data were compared with results initially released by the PHE clinical serology service.",
            "startOffset": 33661,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 40675,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Moreover, while the vaccine response appeared higher for MenC in the ACWY-TT group, both pre- and post-booster GMTs for MenC appeared higher in the MenC-CRM than in the ACWY-TT group (Table 3).",
            "startOffset": 40482,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 29341,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In the initial study (NCT00674583), healthy children, 2\u201310 years of age, were randomized to receive a single dose of either MenACWY-TT (ACWY-TT group) or MenC-CRM197 (MenC-CRM group).",
            "startOffset": 29158,
            "title": "Study design and children"
        },
        {
            "endOffset": 40902,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "As with the rSBA responses, seroprotection rates to all serogroups in the ACW-TT group and to MenC in the MenC-CRM group were 100% following the booster dose.",
            "startOffset": 40744,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 47524,
            "parents": [],
            "secId": "s0065",
            "sentence": "In general, laboratory variations in the SBA assay limit interpretation.",
            "startOffset": 47452,
            "title": "Discussion"
        },
        {
            "endOffset": 41214,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the persistence TVC, no SAEs considered to be possibly related to vaccination, study procedures or GSK concomitant medication were reported between the end of the primary vaccination phase and M68 post-vaccination.",
            "startOffset": 40997,
            "title": "Safety"
        },
        {
            "endOffset": 32730,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0195": {
                    "endOffset": 32729,
                    "startOffset": 32725
                }
            },
            "secId": "s0025",
            "sentence": "rSBA titers were assessed as previously described [39].",
            "startOffset": 32675,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 47923,
            "parents": [],
            "secId": "s0065",
            "sentence": "In conclusion, with rSBA bacterial antibodies persisting in 52.8\u201386.5% for MenA, W, Y after MenACWY-TT vaccination, this study shows a benefit of vaccination over acquisition of natural immunity for these serogroups.",
            "startOffset": 47707,
            "title": "Discussion"
        },
        {
            "endOffset": 36489,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The longitudinal model was designed considering the group and rSBA titer values at M0 until M68 in the ATP cohorts.",
            "startOffset": 36374,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35285,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In the booster phase, safety analyses were performed on the Booster total vaccinated cohort (TVC) and the immunogenicity was based on the Booster ATP cohort for immunogenicity.",
            "startOffset": 35109,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 46663,
            "parents": [],
            "secId": "s0065",
            "sentence": "A marked increase in antibody levels following vaccination was observed for all serogroups in all boosted children with rSBA GMT fold increases ranging from 42 to 372 in the ACWY-TT group, and 143 for MenC in the MenC-CRM group.",
            "startOffset": 46435,
            "title": "Discussion"
        },
        {
            "endOffset": 27709,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 27708,
                    "startOffset": 27704
                }
            },
            "secId": "s0005",
            "sentence": "given at 12 months of age with a booster dose of MenACWY at 14 years of age [34].",
            "startOffset": 27628,
            "title": "Introduction"
        },
        {
            "endOffset": 41355,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the booster TVC, pain was the most frequently reported solicited local symptom during the 4-day follow-up period in both groups (Fig. 3A).",
            "startOffset": 41214,
            "title": "Safety"
        },
        {
            "endOffset": 45134,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 45133,
                    "startOffset": 45129
                }
            },
            "secId": "s0065",
            "sentence": "In Finland, vaccination of toddlers and children aged 2\u201311 warranted revaccination in a considerably higher proportion of toddlers (49.3%) when compared to the older age group (37.2%), pointing towards a benefit if priming occurs beyond infancy [24].",
            "startOffset": 44884,
            "title": "Discussion"
        },
        {
            "endOffset": 26157,
            "parents": [],
            "secId": "s0005",
            "sentence": "Currently, three quadrivalent meningococcal conjugate vaccines (MenACWY) are available: MenACWY-DT (Menactra, Sanofi Pasteur Inc.), MenACWY-CRM (Menveo, GSK) and MenACWY-TT (Nimenrix, Pfizer).",
            "startOffset": 25965,
            "title": "Introduction"
        },
        {
            "endOffset": 43511,
            "parents": [],
            "refoffsets": {
                "b0215": {
                    "endOffset": 43510,
                    "startOffset": 43506
                }
            },
            "secId": "s0065",
            "sentence": "hSBA titers \u22651:8 were retained by 28.8% for MenA and 73.2% to 80.6% for MenC, W and Y. For MenC-CRM-vaccinees, the percentages for MenC antibody persistence at year 4 were 35.6% (rSBA) and 46.9% (hSBA) [43].",
            "startOffset": 43304,
            "title": "Discussion"
        },
        {
            "endOffset": 36695,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The number and percentage of children with any AEs and the 95% CIs were tabulated overall, by grade and their relationship to vaccination.",
            "startOffset": 36557,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 38691,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In both groups, the rSBA-MenC GMTs decreased around 2-fold from M32 to M68.",
            "startOffset": 38616,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 34419,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the booster phase of the study, specific local (pain, redness and swelling) and general (fatigue, headache, gastrointestinal symptoms and fever) symptoms were recorded for 4 days following vaccination; unsolicited AEs were recorded for one month following vaccination.",
            "startOffset": 34148,
            "title": "Safety assessments"
        },
        {
            "endOffset": 46434,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 46333,
                    "startOffset": 46324
                },
                "b0050": {
                    "endOffset": 46333,
                    "startOffset": 46324
                },
                "b0240": {
                    "endOffset": 46333,
                    "startOffset": 46324
                }
            },
            "secId": "s0065",
            "sentence": "Given the variation in meningococcal disease epidemiology by geographic area and time [8,10,48], vaccination against multiple serogroups may be deemed necessary to protect individuals against IMD.",
            "startOffset": 46238,
            "title": "Discussion"
        },
        {
            "endOffset": 40988,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "There were marked increases in antibody titers seen to all serogroups in both groups.",
            "startOffset": 40903,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 46012,
            "parents": [],
            "secId": "s0065",
            "sentence": "rSBA and hSBA each have their specific assay conditions (i.e., bacterial culture, incubation times, etc.).",
            "startOffset": 45906,
            "title": "Discussion"
        },
        {
            "endOffset": 33419,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For the rSBAs, one positive control was included in each assay and a valid titer had to be obtained for the control.",
            "startOffset": 33303,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 39879,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-booster (M69), the percentage of children with rSBA antibody titers \u22651:8 was 100% for all serogroups in both groups (Table 3).",
            "startOffset": 39738,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 46238,
            "parents": [],
            "secId": "s0065",
            "sentence": "It is thus important to be aware of and highlight the different results obtained with these two assays.",
            "startOffset": 46135,
            "title": "Discussion"
        },
        {
            "endOffset": 47707,
            "parents": [],
            "secId": "s0065",
            "sentence": "Further, this study was not designed to delineate primary immune response and decline in persistence antibodies by age group, further studies are required to validate these findings.",
            "startOffset": 47525,
            "title": "Discussion"
        },
        {
            "endOffset": 39689,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Within the same age group, the MenC rSBA titers \u22651:8 and \u22651:128 and MenC GMTs tended to be slightly higher in the MenC-CRM group when compared to ACWY-TT group, however hSBA results showed comparable MenC titres in the groups (Supplementary Digital Contents 2 and 4).",
            "startOffset": 39422,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 24433,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 24432,
                    "startOffset": 24427
                },
                "b0010": {
                    "endOffset": 24432,
                    "startOffset": 24427
                },
                "b0015": {
                    "endOffset": 24432,
                    "startOffset": 24427
                }
            },
            "secId": "s0005",
            "sentence": "Invasive meningococcal disease (IMD) caused by the bacterium Neisseria meningitidis is associated with high morbidity and mortality [1\u20133].",
            "startOffset": 24295,
            "title": "Introduction"
        },
        {
            "endOffset": 34881,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "SAEs and NOCI (e.g. autoimmune disorders, asthma, type 1 diabetes and allergies) were recorded during a 31-day period following vaccination.",
            "startOffset": 34741,
            "title": "Safety assessments"
        },
        {
            "endOffset": 33009,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Samples obtained at different persistence time points were tested at different times; however, all M68 and M69 samples were tested at the same time.",
            "startOffset": 32861,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 35807,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0205": {
                    "endOffset": 35726,
                    "startOffset": 35722
                },
                "b0210": {
                    "endOffset": 35806,
                    "startOffset": 35802
                }
            },
            "secId": "s0035",
            "sentence": "We calculated exact 95% CIs based on the method by Clopper [41] and standardized asymptotic 95% CIs based on method 6 reported by Newcombe [42].",
            "startOffset": 35663,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 46134,
            "parents": [],
            "secId": "s0065",
            "sentence": "In addition, the different mechanism of action that each of these assays uses might account for the differences observed.",
            "startOffset": 46013,
            "title": "Discussion"
        },
        {
            "endOffset": 40481,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The percentage of children with an rSBA vaccine response for the four serogroups at M69 ranged between 89.1% (MenA) and 97.6% (MenC) in the ACWY-TT group and between 87.3% (MenC) and 98.2% (MenA, W and Y) in the MenC-CRM group (Table 3).",
            "startOffset": 40244,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 44602,
            "parents": [],
            "refoffsets": {
                "b0225": {
                    "endOffset": 44601,
                    "startOffset": 44594
                },
                "b0230": {
                    "endOffset": 44601,
                    "startOffset": 44594
                }
            },
            "secId": "s0065",
            "sentence": "In general, the decline in antibody levels following one dose of vaccine administration seems to be more pronounced when vaccination occurs in infancy and antibody persistence increases with the age of children at primary vaccination [45,46].",
            "startOffset": 44360,
            "title": "Discussion"
        },
        {
            "endOffset": 42646,
            "parents": [],
            "secId": "s0065",
            "sentence": "Overall, antibody persistence in terms of percentage of participants with rSBA titers \u22651:8 and rSBA GMTs varied for serogroups, with higher seropositivity rates and GMTs for MenA and MenY than for the MenC and MenW; MenC being the lowest.",
            "startOffset": 42408,
            "title": "Discussion"
        },
        {
            "endOffset": 30056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In the booster phase of the study, all eligible primed children received a single booster dose of MenACWY-TT.",
            "startOffset": 29947,
            "title": "Study design and children"
        },
        {
            "endOffset": 32861,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For hSBA-MenC titers, the accepted correlate of protection \u22651:4 and the more conservative threshold of hSBA titers \u22651:8 were used.",
            "startOffset": 32731,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 39422,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In the MenC-CRM group, the percentage with hSBA titers \u22651:8 was 35.6% for MenA, 75.4% for MenC, 36.5% for MenW and 41.4% for MenY, respectively (Table 2).",
            "startOffset": 39268,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 32035,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The safety and reactogenicity of MenACWY-TT were evaluated with respect to (1) local and general solicited symptoms during the 4-day period (Days 0\u20133) following vaccination; (2) unsolicited serious and non-serious adverse events (AEs) and new onset of chronic illness (NOCI) (e.g. autoimmune disorders, asthma, type I diabetes and allergies) during the 31-day period (Days 0\u201330) following vaccination.",
            "startOffset": 31634,
            "title": "Study objectives"
        },
        {
            "endOffset": 32404,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants were tested for all serogroups by rSBA assay at each time point and by hSBA assay at M68 and M69.",
            "startOffset": 32294,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 45905,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 45904,
                    "startOffset": 45897
                },
                "b0185": {
                    "endOffset": 45904,
                    "startOffset": 45897
                },
                "b0190": {
                    "endOffset": 45904,
                    "startOffset": 45897
                }
            },
            "secId": "s0065",
            "sentence": "The lack of correlation between the rSBA and hSBA assays has been described by others [36\u201338].",
            "startOffset": 45811,
            "title": "Discussion"
        },
        {
            "endOffset": 37879,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The age, gender and racial distribution characteristics were similar to the ATP cohort for persistence (Supplementary Digital Content 1).",
            "startOffset": 37742,
            "title": "Study participants"
        },
        {
            "endOffset": 30692,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A summary of the protocol is available at http://www.gsk-clinicalstudyregister.com (GSK study ID 113977).",
            "startOffset": 30587,
            "title": "Study design and children"
        },
        {
            "endOffset": 47256,
            "parents": [],
            "secId": "s0065",
            "sentence": "Another limitation was the lack of a MenC-TT control group and a MenC na\u00efve control group to assess the effect of boosting as compared to primary vaccination within the same study and at the same time.",
            "startOffset": 47055,
            "title": "Discussion"
        },
        {
            "endOffset": 25965,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 25937,
                    "startOffset": 25934
                },
                "b0080": {
                    "endOffset": 25905,
                    "startOffset": 25901
                },
                "b0085": {
                    "endOffset": 25964,
                    "startOffset": 25960
                }
            },
            "secId": "s0005",
            "sentence": "MenC vaccine is marketed in Europe, Canada, Australia, and Latin America and was introduced in the national childhood vaccination schedule for children in the second year of life in several European countries [16] such as, in Germany in 2006 [6] and in France in 2010 [17].",
            "startOffset": 25692,
            "title": "Introduction"
        },
        {
            "endOffset": 29946,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Exclusion criteria in the persistence phase included vaccination with a meningococcal vaccine against serogroup A, C, W or Y outside of the primary study and history of meningococcal disease.",
            "startOffset": 29755,
            "title": "Study design and children"
        },
        {
            "endOffset": 30349,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.",
            "startOffset": 30240,
            "title": "Study design and children"
        },
        {
            "endOffset": 35903,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The GMTs were calculated by taking the anti-log of the mean of the log10 titer transformations.",
            "startOffset": 35808,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 40743,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "hSBA data post-booster are given in Supplementary Digital Content 6.",
            "startOffset": 40675,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 41892,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Grade 3 solicited general symptoms were rarely reported (the most frequent being headache reported by 7/169 [4.1%] children in the ACWY-TT group).",
            "startOffset": 41746,
            "title": "Safety"
        },
        {
            "endOffset": 33153,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For the hSBA assay, two quality positive controls (QC) were included on each plate.",
            "startOffset": 33070,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 25530,
            "parents": [],
            "secId": "s0005",
            "sentence": "In view of these epidemiological data, vaccination against multiple serogroups is considered the best strategy to protect individuals against a broader range of IMD in a single injection.",
            "startOffset": 25343,
            "title": "Introduction"
        },
        {
            "endOffset": 42108,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "During the 31-day period after vaccination, 26/179 (14.5%) children in the ACWY-TT group and 8/62 (12.9%) children in the MenC-CRM group reported at least one unsolicited symptom.",
            "startOffset": 41929,
            "title": "Safety"
        },
        {
            "endOffset": 44360,
            "parents": [],
            "secId": "s0065",
            "sentence": "An increase in the seropositivity rate such as for MenY from M44 to M56 could be a result of assay variability, a common observation with functional assays such as the SBA assays, given that the M44 and M56 samples were tested at different times.",
            "startOffset": 44114,
            "title": "Discussion"
        },
        {
            "endOffset": 38615,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In the ACWY-TT group, the percentages of children with rSBA titers \u22651:8 for MenA, MenW, and MenY were 86.5%, 52.8% and 71.3%, respectively, while the percentages with rSBA titers \u22651:8 for MenA, MenW, and MenY were 29.5%, 14.8% and 13.1%, respectively, in the MenC-CRM group.",
            "startOffset": 38341,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 26695,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 26694,
                    "startOffset": 26687
                },
                "b0115": {
                    "endOffset": 26694,
                    "startOffset": 26687
                },
                "b0120": {
                    "endOffset": 26694,
                    "startOffset": 26687
                }
            },
            "secId": "s0005",
            "sentence": "Booster vaccination in toddlers and adolescents has been shown to elicit robust memory responses [22\u201324].",
            "startOffset": 26590,
            "title": "Introduction"
        },
        {
            "endOffset": 48736,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our findings support the observation that besides epidemiological variations, age at primary vaccination is essential as presented in our study by (1) children boosted 5 years after a primary dose as young children and (2) adolescents 5 years after a primary dose as older children.",
            "startOffset": 48454,
            "title": "Discussion"
        },
        {
            "endOffset": 24813,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 24655,
                    "startOffset": 24650
                },
                "b0025": {
                    "endOffset": 24655,
                    "startOffset": 24650
                },
                "b0030": {
                    "endOffset": 24761,
                    "startOffset": 24758
                },
                "b0035": {
                    "endOffset": 24775,
                    "startOffset": 24772
                }
            },
            "secId": "s0005",
            "sentence": "Until recently, meningococcal serogroups B (MenB) with 68.0% of IMD cases and C (MenC) with 17.0% were the most prevalent in Europe [4,5] with estimates from Germany (2002\u20132010) and France (2012) showing that MenC was responsible for 25.0% [6] and 27.0% [7] of confirmed IMD cases, respectively.",
            "startOffset": 24518,
            "title": "Introduction"
        },
        {
            "endOffset": 26411,
            "parents": [],
            "secId": "s0005",
            "sentence": "Previous clinical studies have shown that MenACWY-TT is immunogenic and well-tolerated in toddlers, children, adolescents, and adults.",
            "startOffset": 26277,
            "title": "Introduction"
        },
        {
            "endOffset": 41496,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the ACWY-TT group, grade 3 pain, redness and swelling were reported by 7 (4.1%), 8 (4.7%) and 4 (2.3%) out of 171 children, respectively.",
            "startOffset": 41356,
            "title": "Safety"
        },
        {
            "endOffset": 46802,
            "parents": [],
            "secId": "s0065",
            "sentence": "The safety results suggest that both primary and booster doses of MenACWY-TT have a clinically acceptable safety profile in young children.",
            "startOffset": 46663,
            "title": "Discussion"
        },
        {
            "endOffset": 27627,
            "parents": [],
            "secId": "s0005",
            "sentence": "Due to the success of the MenC vaccination program and herd protection of infants, in 2016 the schedule was revised and currently a primary dose is.",
            "startOffset": 27479,
            "title": "Introduction"
        },
        {
            "endOffset": 31634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The secondary objectives were: (1) to evaluate the long-term persistence of the immunogenicity of MenACWY-TT at M32, M44, M56, and M68 overall and stratified by age; (2) to evaluate the immunogenicity of a booster vaccination given at M68 in terms of percentages of children with: (i) rSBA (antibody titers \u22651:8, \u22651:128, and geometric mean titers [GMTs]) at one month post-booster vaccination; and (ii) human complement (hSBA) (antibody titers \u22651:4, \u22651:8 and GMTs) at one month post-booster vaccination for all serogroups; and (3) to evaluate the immunogenicity of a booster vaccination in terms of the percentage of children with rSBA vaccine responses for all serogroups at one month post-booster vaccination.",
            "startOffset": 30923,
            "title": "Study objectives"
        },
        {
            "endOffset": 26803,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 26802,
                    "startOffset": 26798
                }
            },
            "secId": "s0005",
            "sentence": "Long-term protection against IMD was suggested to be related to the presence of circulating antibodies [25].",
            "startOffset": 26695,
            "title": "Introduction"
        },
        {
            "endOffset": 37741,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of these, 236 children (97.9%) were included in the Booster ATP cohort for safety and 220 children (91.3%) were included in the Booster ATP cohort for immunogenicity (Fig. 1).",
            "startOffset": 37566,
            "title": "Study participants"
        },
        {
            "endOffset": 30239,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol and associated documents were reviewed and approved by local ethics committees.",
            "startOffset": 30141,
            "title": "Study design and children"
        },
        {
            "endOffset": 35108,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In the persistence phase of the study, results are presented for the according-to-protocol (ATP) cohorts for persistence at M32, M44, M56 and M68, overall and stratified by age (2\u20135 years and 6\u201310 years).",
            "startOffset": 34904,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 32293,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0200": {
                    "endOffset": 32292,
                    "startOffset": 32288
                }
            },
            "secId": "s0025",
            "sentence": "Blood samples were collected at each persistence and the booster timepoints and functional anti-meningococcal activity was determined by rSBA and hSBA assays, based on the Centers for Disease Control and Prevention protocol [40].",
            "startOffset": 32064,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 26277,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 26276,
                    "startOffset": 26269
                },
                "b0095": {
                    "endOffset": 26276,
                    "startOffset": 26269
                }
            },
            "secId": "s0005",
            "sentence": "In Europe, MenACWY-CRM and MenACWY-TT are licensed for children aged \u22652 years, and as of 6 weeks, respectively [18,19].",
            "startOffset": 26158,
            "title": "Introduction"
        },
        {
            "endOffset": 44883,
            "parents": [],
            "secId": "s0065",
            "sentence": "Likewise, post-primary GMTs were observed to be higher in this age group.",
            "startOffset": 44810,
            "title": "Discussion"
        },
        {
            "endOffset": 40131,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The rSBA GMTs against MenA, MenC, MenW, and MenY at M69 increased 42-, 372-, 258-, and 64-fold in the ACWY-TT group; the rSBA GMTs against MenC at M69 increased 143-fold in the MenC-CRM group compared to M68 (Table 3, Supplementary Digital Content 5).",
            "startOffset": 39880,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 40244,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The MenC-CRM group was only boosted for MenC at M69 and received a primary vaccination for MenA, MenW, and MenY.",
            "startOffset": 40132,
            "title": "Immunogenicity of a booster dose of MenACWY-TT"
        },
        {
            "endOffset": 42317,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At least one grade 3 unsolicited symptom was reported by 3/179 (1.7%) children in the ACWY-TT group (viral infection, headache, vomiting) and by 1 child (out of 62; 1.6%) in the MenC-CRM group (otitis media).",
            "startOffset": 42109,
            "title": "Safety"
        },
        {
            "endOffset": 29681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We present here the persistence at 32, 44, 56, and 68 M post-vaccination, overall and stratified by age (2\u20135 years and 6\u201310 years), and the immunogenicity and safety one month after booster vaccination of MenACWY-TT administered to all study participants at M68.",
            "startOffset": 29419,
            "title": "Study design and children"
        },
        {
            "endOffset": 29755,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "refoffsets": {
                "b0195": {
                    "endOffset": 29754,
                    "startOffset": 29750
                }
            },
            "secId": "s0015",
            "sentence": "The vaccine composition of MenACWY-TT has been previously described [39].",
            "startOffset": 29682,
            "title": "Study design and children"
        },
        {
            "endOffset": 30141,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Additional criteria applicable to the booster phase can be found in the supplements.",
            "startOffset": 30057,
            "title": "Study design and children"
        },
        {
            "endOffset": 34640,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Redness and swelling were considered of grade 3 intensity if their diameter was >50 mm and grade 3 fever was defined as axillary/oral temperature >39.5 \u00b0C.",
            "startOffset": 34485,
            "title": "Safety assessments"
        },
        {
            "endOffset": 38094,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The estimated values from the longitudinal modeling analyses performed at M68 for rSBA-MenA, C, W and Y for ACWY-TT group and for rSBA-MenC for MenC-CRM group were similar to the observed values for each time point.",
            "startOffset": 37879,
            "title": "Study participants"
        },
        {
            "endOffset": 46922,
            "parents": [],
            "secId": "s0065",
            "sentence": "Limitations of this study include its open design, which could potentially have led to bias in reactogenicity reporting.",
            "startOffset": 46802,
            "title": "Discussion"
        },
        {
            "endOffset": 38340,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In the ATP persistence cohort at M68 after vaccination, the percentages of children who retained rSBA titers \u22651:8 for MenC were 39.9% in the ACWY-TT group and 62.3% in the MenC-CRM group (Table 2).",
            "startOffset": 38143,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 41929,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "There was no grade 3 fever reported.",
            "startOffset": 41893,
            "title": "Safety"
        },
        {
            "endOffset": 26982,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 26981,
                    "startOffset": 26968
                },
                "b0120": {
                    "endOffset": 26981,
                    "startOffset": 26968
                },
                "b0130": {
                    "endOffset": 26981,
                    "startOffset": 26968
                },
                "b0135": {
                    "endOffset": 26981,
                    "startOffset": 26968
                }
            },
            "secId": "s0005",
            "sentence": "Antibody persistence data after infant/toddler vaccination with multivalent meningococcal conjugate vaccines are currently available up to 5 years post-vaccination [23,24,26,27].",
            "startOffset": 26804,
            "title": "Introduction"
        },
        {
            "endOffset": 36036,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibody titers below the cut-off of the assay were given an arbitrary value of half the cut-off for the purpose of GMT calculation.",
            "startOffset": 35904,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 43122,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 43121,
                    "startOffset": 43117
                }
            },
            "secId": "s0065",
            "sentence": "A study performed in the US, showed hSBA titers \u22651:8 at year 5 in children between 64.0% and 75.0% for MenC, MenW and MenY, and 31.7% for MenA after one dose of MenACWY-TT at 12 M of age [23].",
            "startOffset": 42930,
            "title": "Discussion"
        },
        {
            "endOffset": 26589,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 26588,
                    "startOffset": 26581
                },
                "b0105": {
                    "endOffset": 26588,
                    "startOffset": 26581
                }
            },
            "secId": "s0005",
            "sentence": "Non-inferiority of MenACWY-TT compared to a licensed quadrivalent plain polysaccharide vaccine was shown in two previous studies conducted in children 2\u201310 years of age [20,21].",
            "startOffset": 26412,
            "title": "Introduction"
        },
        {
            "endOffset": 44114,
            "parents": [],
            "secId": "s0065",
            "sentence": "Given the short incubation period for development of IMD, reliance on immunological memory may not be sufficient to protect vaccinated individuals and a booster may be required.",
            "startOffset": 43937,
            "title": "Discussion"
        },
        {
            "endOffset": 33660,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Public Health England (PHE) monitored the stability of rSBA with the help of an Internal Quality assurance process (IQA) consisting of monthly re-testing of approximately 2% of samples (minimum four per serogroup) tested the previous month.",
            "startOffset": 33420,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 47451,
            "parents": [],
            "secId": "s0065",
            "sentence": "As a drawback, the change in rSBA assays from the primary study to the persistence phase constrained the interpretation of decay in SBA levels from post-primary up to the persistence timepoints.",
            "startOffset": 47257,
            "title": "Discussion"
        },
        {
            "endOffset": 27186,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0120": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0125": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0140": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0145": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0150": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0155": {
                    "endOffset": 27185,
                    "startOffset": 27172
                },
                "b0160": {
                    "endOffset": 27185,
                    "startOffset": 27172
                }
            },
            "secId": "s0005",
            "sentence": "These studies have shown that serum antibody levels elicited by meningococcal conjugate vaccines wane over time, especially at younger ages, suggesting that a booster dose may be warranted [23\u201325,28\u201332].",
            "startOffset": 26983,
            "title": "Introduction"
        },
        {
            "endOffset": 35663,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For the booster phase, TVC was defined as all subjects with a documented vaccination during the booster phase.",
            "startOffset": 35553,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42397,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Neither SAEs nor NOCI were reported within the 31 days post-booster vaccination.",
            "startOffset": 42317,
            "title": "Safety"
        },
        {
            "endOffset": 30923,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective was to evaluate the long-term persistence of the immunogenicity of MenACWY-TT at M32, M44, M56, and M68 in terms of percentages of children with rSBA antibody titers \u22651:8 for all serogroups.",
            "startOffset": 30711,
            "title": "Study objectives"
        },
        {
            "endOffset": 30516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We obtained informed consent from the parent or guardian of each child before performing any study-specific procedures (for country specific details see supplements).",
            "startOffset": 30350,
            "title": "Study design and children"
        },
        {
            "endOffset": 38863,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "GMTs against MenA, MenW, and MenY decreased by approximately 1.5\u20133.6-fold from M32 through M68 in the ACWY-TT group, and ranged from 59.2 (MenW) to 139.4 (MenY) (Table 2).",
            "startOffset": 38692,
            "title": "Long-term persistence of functional antibodies"
        },
        {
            "endOffset": 41638,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In the MenC-CRM group, grade 3 pain, redness and swelling, were reported by 4 (6.7%), 4 (6.7%) and 3 (5.0%) out of 60 children, respectively.",
            "startOffset": 41497,
            "title": "Safety"
        },
        {
            "endOffset": 48094,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although antibodies wane over time irrespective of age at vaccination, the primary response and decline seem to be age dependent as has been observed in previous studies.",
            "startOffset": 47924,
            "title": "Discussion"
        },
        {
            "endOffset": 33303,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Material and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A monthly review of all QC data was also performed.",
            "startOffset": 33252,
            "title": "Immunogenicity assessments"
        }
    ],
    "docId": "S0264410X18305619",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Markus",
                "initial": "M.",
                "last": "Knuf"
            },
            {
                "email": null,
                "first": "Klaus",
                "initial": "K.",
                "last": "Helm"
            },
            {
                "email": null,
                "first": "Devayani",
                "initial": "D.",
                "last": "Kolhe"
            },
            {
                "email": "marie.x.van-der-wielen@gsk.com",
                "first": "Marie",
                "initial": "M.",
                "last": "Van Der Wielen"
            },
            {
                "email": null,
                "first": "Yaela",
                "initial": "Y.",
                "last": "Baine"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.04.064",
        "firstpage": "3286",
        "issn": "0264410X",
        "keywords": [
            "Antibody persistence",
            "Booster response",
            "Children",
            "Conjugate vaccine",
            "Quadrivalent meningococcal vaccine"
        ],
        "lastpage": "3295",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Antibody persistence and booster response 68\u202fmonths after vaccination at 2\u201310\u202fyears of age with one dose of MenACWY-TT conjugate vaccine"
    }
}